Fixed-Combination Hypertension Drugs Get Clearer Regulatory Pathway, But Will Pharma Follow?
Significant effects are expected to be observed on both systolic and diastolic blood pressures, US FDA final guidance says in lone substantive change from January draft aimed at streamlining development for multi-drug combinations of previously approved products; with only five such products in the clinical pipeline according to Biomedtracker data, there appears to be little big pharma interest in this space.
You may also be interested in...
Sponsors will need fewer dosage comparisons in factorial studies of fixed-dose hypertension combination products under the draft guidance.
US FDA declined stakeholder requests to remove recommendation for placebo controls from a final guidance but added qualifying language on their use ‘when feasible.’ While the agency excised language on biomarker validation from the final guidance, it reaffirmed the need for early establishment of critical quality attributes and critical process parameters.
Oncologic Drugs Advisory Committee votes 6-5 that ramucirumab’s benefit/risk profile is favorable in first-line lung cancer, but 13-2 that pivotal trial data do not support approval of Steba’s vascular-targeted, photodynamic therapy for low-risk prostate cancer.